VERGE GENOMICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN NOVEMBER
• Piper Sandler 34th Annual Healthcare Conference on November 29
Evercore ISI HealthCONx Conference 2022 on November 30
San Francisco, CA, November 21, 2022 – Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Alice Zhang, CEO and co-founder of Verge Genomics, will present at both the Piper Sandler 34th Annual Healthcare Conference on November 29 in New York, and the 5th Annual Evercore ISI HealthCONx Conference 2022 on November 30. Please see additional information below:
Piper Sandler 34th Annual Healthcare Conference
Presentation: Tuesday, November 29
Time: 10:30-10:50am ET
Presenter: Alice Zhang, CEO and co-founder
5th Annual Evercore ISI HealthCONx Conference 2022
Presentation: Wednesday, November 30
Time: 10:30-10:50am ET
Presenter: Alice Zhang, CEO and co-founder
About Verge Genomics
Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human, AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.
Verge is one of the first AI-enabled drug discovery companies to independently develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.
For additional information, please visit VergeGenomics.com. Follow us on LinkedIn and Twitter.
CONTACTS:
Verge Genomics
Adam Silverstein
Scient PR
adam@scientpr.com